Skip to content
Bio Medica Laboratories logo

Bio Medica Laboratories IPO

Check allotment status
Issue price
₹139
Listing price
₹111.2
-20.00%
Current price
₹150
+7.91%
Subscribed
2.31x
Issue size
₹52 Cr
Listed on
29 May 2026

IPO timeline

  1. Opens
    21 MayThu
  2. Closes
    25 MayMon
  3. Allotment
    26 MayTue
  4. Refunds
    27 MayWed
  5. Demat credit
    27 MayWed
  6. Listing
    29 MayFri

Issue details

Price band
₹132 – ₹139 per share
Issue size
₹52 Cr
Fresh issue
Not available
Offer for sale
Not available
Issue type
Fresh capital cum OFS
Face value
₹10 per share
Lot size
1,000 shares
Minimum investment
₹1,39,000
Listing on
NSE SME
Exchange code
BMLL-SM · BMLL

This issue combines a fresh issue and an offer for sale. The amounts for each part are not available in our data; see the offer document for the split.

Lot size and investment

ApplicationLotsSharesAmount
Retail (Min)11,000₹1,39,000
Retail (Max)11,000₹1,39,000
HNI (Min)22,000₹2,78,000

Reservation

QIB
36,000 shares (1.00% of the Offer)
NII
17,55,000 shares (48.98% of the Offer)
Retail
17,92,000 shares (50.01% of the Offer)

Allotment status

Registrar: Skyline Financial Services Private Limited

The allotment for this IPO is final. Check whether you received shares on the registrar's website using your PAN, application number or demat account (DP / Client ID).

Check allotment on Skyline Financial Services
  1. 1Open the registrar's allotment page and select this IPO from the list.
  2. 2Enter your PAN, application number or DP / Client ID.
  3. 3Submit to see the number of shares allotted, if any.
Basis of allotment
26 May 2026
Refunds initiated
27 May 2026
Shares credited to demat
27 May 2026
Listing
29 May 2026

Grey market premium (GMP)

Updated 27 May 2026, 12:02 PM IST
Current GMP
₹2
+1.00%
Estimated listing price
₹141
Issue price ₹139
Highest
₹4
22 May
Lowest
₹0
18 May

GMP by day (₹ per share)

Day-wise GMP table
DateGMPPremiumEst. listing
27 May 2026₹2+1.00%₹141
26 May 2026₹2+1.00%₹141
25 May 2026₹0—₹139
23 May 2026₹2+1.00%₹141
22 May 2026₹4+3.00%₹143
21 May 2026₹0—₹139
20 May 2026₹0—₹139
19 May 2026₹0—₹139
18 May 2026₹0—₹139
Kostak rate
₹0

GMP is an unofficial indicator from an unregulated market. It is shown for information only and is not a prediction of the listing price or a recommendation to apply.

Subscription status

Updated 25 May 2026, 05:00 PM IST
Overall subscription
2.31x
Fully subscribed
  • QIB15.94x
  • NII (HNI)1.41x
  • Retail2.92x
CategoryShares offeredShares bid forSubscribed
Qualified Institutional Buyers (QIB)36,0005,74,00015.94x
Non-Institutional Investors (NII)17,55,00024,75,0001.41x
Retail Individual Investors (RII)17,92,00052,26,0002.92x
Total35,83,00082,75,0002.31x

Financials

Amounts in Rs. Crore
P/E Ratio
13.45
EPS (₹)
10.33
RoCE
48.20%
RoNW
99.59%
PAT Margin
25.64%

Separate pre- and post-issue P/E are not available for this IPO; the P/E shown is as disclosed for the issue.

Period ended30 Nov 202531 Mar 202531 Mar 202431 Mar 2023
Assets65.1739.1219.5317.57
Total Income28.6338.3315.3416.25
Profit After Tax8.669.792.500.33
EBITDA13.4515.215.631.70
NET Worth17.1214.734.942.44
Reserves and Surplus7.945.554.842.34
Total Borrowing38.1715.0110.499.61
CompanyIssue sizeP/ERoNWPAT marginSubscribedListing gain
Bio Medica Laboratories
This IPO
₹52 Cr13.4599.59%25.64%2.31x-20.00%
Pramodini Medicare
SME · listed 19 Aug 2026
₹69.04 Cr14.9732.69%27.90%3.66x+1.69%
ABH Healthcare
SME · listed 1 Sep 2026
₹34.98 Cr20.6939.07%10.74%1.42x-2.94%
Avience Biomedicals
SME · listed 25 Jun 2026
₹30.24 Cr16.5649.89%15.86%385.4x+90.00%
Speciality Medicines
SME · listed 30 Mar 2026
₹29 Cr10.4928.30%14.77%2.19x0.00%
Credent Connect N Care
SME · listed 20 Aug 2026
₹93.9 Cr18.6814.13%2.88%142.38x+90.00%
Himalaya Nutravedics India
SME · listed 29 Sep 2026
₹26.5 Cr12.6345.12%17.16%2.24x+11.32%

Peers are other recent IPOs from the same industry, closest in issue size. Ratios are as disclosed at the time of each issue. This is not the listed-peer table from the offer document.

IPO objectives

₹47.19 Cr total

How Bio Medica Laboratories plans to use the money raised, as stated in the offer document.

  1. Repayment of loan₹6.5 Cr
  2. Enhancement of its existing production capabilities by setting up of new manufacturing facility at the existing premises₹28.5 Cr
  3. General Corporate Purposes₹7.05 Cr
  4. Issue Expense₹5.14 Cr

About Bio Medica Laboratories

Bio Medica Laboratories is an Indian pharmaceutical company engaged in the manufacturing and marketing of a wide range of healthcare and medicinal products. The company has built its presence in the pharmaceutical sector through quality-focused manufacturing practices and a diversified product portfolio catering to hospitals, clinics, and retail healthcare markets. Over the years, it has expanded its operations by focusing on customer relationships, product reliability, and compliance with industry standards. The company operates on a business model centred around the development, production, and distribution of pharmaceutical formulations and healthcare solutions across multiple therapeutic segments. Its product offerings include tablets, capsules, syrups, injections, and other medical formulations supplied through distributors and healthcare networks. The business is promoted by experienced industry professionals who focus on expanding market reach, improving manufacturing capabilities, and strengthening the company’s position in the domestic pharmaceutical industry.

Strengths

  • Experienced promoters and management team with pharma industry knowledge.
  • Diversified portfolio of injectable pharmaceutical products for human and veterinary use.
  • Strong quality assurance systems supported by GMP-certified manufacturing facilities.
  • Established relationships with clients across multiple Indian states and healthcare markets.
  • Significant improvement in revenue, EBITDA margins, and profitability during recent financial years.

Risks

  • High dependence on key customers may impact revenue if orders decline.
  • Any quality control failure could damage reputation and invite legal liabilities.
  • Failure to adopt new pharmaceutical technologies may affect future competitiveness.
  • Negative cash flow risks may create pressure on expansion and working capital needs.
  • The company operates from premises that are not fully owned, creating operational dependency risks.

Promoters and shareholding

Mukesh Mehta and Pradeep Mehta

Promoter holding, pre-issue
99.99
Promoter holding, post-issue
67.7%

Registrar, lead managers and documents

Registrar

Skyline Financial Services Private Limited

011-26812682

ipo@skylinerta.com

Company contact

Plot No.11B-11C, Sector-E, Sanwer Road, Industrial Area, Industrial Estate, Indore, Madhya Pradesh, 452015

+91 7314102751

companysecretary@biomedica.co.in

Bio Medica Laboratories IPO: common questions

1.When does the Bio Medica Laboratories IPO open and close?

The Bio Medica Laboratories IPO opens on 21 May 2026 and closes on 25 May 2026.

2.What is the price band of the Bio Medica Laboratories IPO?

The price band is ₹132 – ₹139 per share, with a lot size of 1,000 shares and a minimum investment of ₹1,39,000.

3.What is the size of the Bio Medica Laboratories IPO?

The issue size is ₹52 Cr (Fresh capital cum OFS).

4.What is the GMP of the Bio Medica Laboratories IPO?

The last reported grey market premium is ₹2 per share as of 27 May 2026, 12:02 PM IST. GMP is unofficial and changes frequently.

5.When is the Bio Medica Laboratories IPO allotment?

The basis of allotment is expected on 26 May 2026. Allotment status can be checked with the registrar, Skyline Financial Services Private Limited.

6.When will the Bio Medica Laboratories IPO list?

The shares listed on 29 May 2026 on NSE SME.

7.Who is the lead manager of the Bio Medica Laboratories IPO?

The book running lead manager is Narnolia Financial Services Ltd, and the registrar is Skyline Financial Services Private Limited.

8.What will the money raised in the Bio Medica Laboratories IPO be used for?

As stated in the offer document, the proceeds are for: Repayment of loan; Enhancement of its existing production capabilities by setting up of new manufacturing facility at the existing premises; General Corporate Purposes; Issue Expense.

9.How can my company launch an IPO like Bio Medica Laboratories?

Start with an IPO readiness assessment: eligibility for the NSE Emerge or BSE SME platform, audited financials, governance, conversion to a public limited company and an indicative valuation. Be IPO Ready advises promoters through each step, from readiness to listing day.

For business owners

Your company could be the next listing

Businesses like these raise growth capital on the public markets every week. Tell us about yours and our advisors will tell you, plainly, whether an IPO is within reach and what it would take.

  • Eligibility check against NSE Emerge, BSE SME and Main Board norms
  • Indicative valuation and issue size for your business
  • A clear timeline from readiness to listing day

Check if your business can list

Fill in the eligibility form and get an assessment of where you stand. It takes about five minutes.

Prefer to talk? Call +91 92130 20393